{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T05:42:16Z","timestamp":1775108536497,"version":"3.50.1"},"reference-count":32,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T00:00:00Z","timestamp":1775088000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To investigate the clinical efficacy and immunomodulatory effects of curcumin (Cur) combined with vedolizumab (VDZ) in patients with moderate-to-severe ulcerative colitis (UC).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A prospective, multicenter, randomized controlled double-blind study was conducted. Patients with moderate-to-severe UC admitted between March 2021 and March 2024 were enrolled and randomly assigned to either the VDZ monotherapy group (76 cases) or the VDZ combined with Cur combination group (83 cases). The treatment period was 26 weeks. The primary outcome was the clinical remission rate at 26 weeks. Secondary outcomes included the remission rate at 14 weeks, the disease activity index (DAI), inflammatory and immune markers, and safety.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The combination group showed significantly higher clinical remission rates at both 26 and 14 weeks compared to the VDZ group (\n                      <jats:italic>P<\/jats:italic>\n                      &amp;lt; 0.05). DAI scores decreased significantly over time in both groups (\n                      <jats:italic>P<\/jats:italic>\n                      &amp;lt; 0.05), with a greater reduction observed in the combination group at both 14 and 26 weeks (\n                      <jats:italic>P<\/jats:italic>\n                      &amp;lt; 0.05). The combination group demonstrated more significant improvements in inflammatory and immune markers: at 26 weeks, CRP, Th17\/Treg ratio, and fecal calprotectin levels were lower than those in the VDZ group (\n                      <jats:italic>P<\/jats:italic>\n                      &amp;lt; 0.05), while IL-10 levels were higher at 14 weeks (\n                      <jats:italic>P<\/jats:italic>\n                      &amp;lt; 0.05). No statistically significant difference in the incidence of adverse reactions was observed between the two groups (\n                      <jats:italic>P<\/jats:italic>\n                      &amp;gt; 0.05), indicating comparable safety profiles. In the combination group, DAI exhibited a stronger positive correlation with Th17\/Treg ratio, CRP, and fecal calprotectin, and a more pronounced negative correlation with IL-10 (\n                      <jats:italic>P<\/jats:italic>\n                      &amp;lt; 0.05). Subgroup analysis showed that both the VDZ group and the combination group had higher benefits in moderate UC compared to severe UC.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Curcumin as an combination group to VDZ significantly improves clinical remission rates, alleviates inflammatory and immune imbalances in patients with moderate-to-severe UC, without increasing safety risks, highlighting its important clinical translational value. This study provides new evidence for combination treatment strategies in UC.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fmed.2026.1789083","type":"journal-article","created":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T04:16:30Z","timestamp":1775103390000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Effect of curcumin combined with vedolizumab on disease activity in patients with moderate to severe ulcerative colitis and its correlation with inflammatory and immune factors"],"prefix":"10.3389","volume":"13","author":[{"given":"Ye","family":"Zhao","sequence":"first","affiliation":[{"name":"Gastroenterology Department, Beijing Hospital of Integrated Traditional Chinese and Western Medicine","place":["Beijing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ming","family":"Bao","sequence":"additional","affiliation":[{"name":"Cadre Diagnosis and Treatment Department, PLA General Hospital","place":["Beijing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wencui","family":"Niu","sequence":"additional","affiliation":[{"name":"Nutrition Department, Beijing Hospital of Integrated Traditional Chinese and Western Medicine","place":["Beijing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,4,2]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"2299","DOI":"10.1016\/j.cgh.2024.04.019","article-title":"Effects of thiopurine withdrawal on vedolizumab-treated patients with ulcerative colitis: a randomized controlled trial","volume":"22","author":"Pudipeddi","year":"2024","journal-title":"Clin Gastroenterol Hepatol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1507009","DOI":"10.3389\/fphar.2025.1507009","article-title":"The adjunctive role of metformin in patients with mild to moderate ulcerative colitis: a randomized controlled study","volume":"16","author":"Binsaleh","year":"2025","journal-title":"Front Pharmacol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"20","DOI":"10.47852\/bonviewMEDIN32021546","article-title":"Stefan-van Staden R-I. The importance of KRAS quantification for a clinicopathological characterization in colorectal cancer patients","volume":"1","author":"Bratei","year":"2024","journal-title":"Medinformatics"},{"key":"B4","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1080\/17474124.2025.2488884","article-title":"Medical management of acute severe ulcerative colitis in the hospitalized patient","volume":"19","author":"Rabinowitz","year":"2025","journal-title":"Expert Rev Gastroenterol Hepatol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1053\/j.gastro.2021.06.015","article-title":"Histologic outcomes with vedolizumab versus adalimumab in ulcerative colitis: results from an efficacy and safety study of vedolizumab intravenous compared to adalimumab subcutaneous in participants with ulcerative colitis (VARSITY)","volume":"161","author":"Peyrin-Biroulet","year":"2021","journal-title":"Gastroenterology"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1763","DOI":"10.1136\/gutjnl-2024-332489","article-title":"Acute severe ulcerative colitis trials: the past, the present and the future","volume":"73","author":"Honap","year":"2024","journal-title":"Gut."},{"key":"B7","doi-asserted-by":"publisher","first-page":"4419","DOI":"10.3390\/jcm14134419","article-title":"Efficacy and safety of infliximab and vedolizumab maintenance therapy in patients with Crohn's disease and ulcerative colitis: a systematic review and meta-analysis","volume":"14","author":"Sands","year":"2025","journal-title":"J Clin Med."},{"key":"B8","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1053\/j.gastro.2019.08.027","article-title":"Efficacy and safety of vedolizumab subcutaneous formulation in a randomized trial of patients with ulcerative colitis","volume":"158","author":"Sandborn","year":"2020","journal-title":"Gastroenterology"},{"key":"B9","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1159\/000526646","article-title":"Curcumin-QingDai combination as treatment for moderate-severe ulcerative colitis","volume":"16","author":"Ben-Horin","year":"2022","journal-title":"Case Rep Gastroenterol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"e2300598","DOI":"10.1002\/mnfr.202300598","article-title":"Curcumin attenuates dextran sodium sulfate induced colitis in obese mice","volume":"68","author":"Kang","year":"2024","journal-title":"Mol Nutr Food Res."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1080\/17474124.2020.1808460","article-title":"Curcumin therapy for ulcerative colitis remission: systematic review and meta-analysis","volume":"14","author":"Goulart","year":"2020","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"113770","DOI":"10.1016\/j.intimp.2024.113770","article-title":"Effect of curcumin regulated memory Th7 cells in mice with DSS-induced colitis","volume":"145","author":"Song","year":"2025","journal-title":"Int Immunopharmacol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1093\/gastro\/goab026","article-title":"Comparing the clinical application values of the Degree of Ulcerative Colitis Burden of Luminal Inflammation (DUBLIN) score and Ulcerative Colitis Endoscopic Index of Severity (UCEIS) in patients with ulcerative colitis","volume":"9","author":"Zhang","year":"2021","journal-title":"Gastroenterol Rep."},{"key":"B14","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1038\/s41577-024-01008-6","article-title":"Strategies for targeting cytokines in inflammatory bowel disease","volume":"24","author":"Neurath","year":"2024","journal-title":"Nat Rev Immunol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"169","DOI":"10.15403\/jgld-177","article-title":"Trefoil factor 3 is highly predictive of complete mucosal healing independently and in combination with C-reactive protein in patients with ulcerative colitis","volume":"28","author":"Nakov","year":"2019","journal-title":"J Gastrointestin Liver Dis."},{"key":"B16","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1007\/s10620-013-2907-3","article-title":"Correlations of C-reactive protein levels and erythrocyte sedimentation rates with endoscopic activity indices in patients with ulcerative colitis","volume":"59","author":"Yoon","year":"2014","journal-title":"Dig Dis Sci."},{"key":"B17","doi-asserted-by":"publisher","first-page":"154287","DOI":"10.1016\/j.phymed.2022.154287","article-title":"Astragaloside IV alleviates ulcerative colitis by regulating the balance of Th17\/Treg cells","volume":"104","author":"Zhong","year":"2022","journal-title":"Phytomedicine."},{"key":"B18","doi-asserted-by":"publisher","first-page":"2145843","DOI":"10.1080\/19490976.2022.2145843","volume":"14","author":"Jia","year":"2022","journal-title":"Gut Microbes."},{"key":"B19","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.14309\/ajg.0000000000003463","article-title":"ACG clinical guideline update: ulcerative colitis in adults","volume":"120","author":"Rubin","year":"2025","journal-title":"Am J Gastroenterol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1733","DOI":"10.1093\/ecco-jcc\/jjad087","article-title":"A comparative evaluation of the measurement properties of three histological indices of mucosal healing in ulcerative colitis: Geboes score, Robarts Histopathology Index and Nancy Index","volume":"17","author":"Peyrin-Biroulet","year":"2023","journal-title":"J Crohns Colitis."},{"key":"B21","doi-asserted-by":"publisher","first-page":"82","DOI":"10.2152\/jmi.71.82","article-title":"Symptomatic adverse events of chemotherapy in breast cancer patients: using CTCAE, PRO-CTCAE, and EORTC QLQ-C30","volume":"71","author":"Arahori","year":"2024","journal-title":"J Med Invest."},{"key":"B22","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1093\/ecco-jcc\/jjad203","article-title":"Biologic therapy for inflammatory bowel disease: real-world comparative effectiveness and impact of drug sequencing in 13 222 patients within the UK IBD BioResource","volume":"18","author":"Kapizioni","year":"2024","journal-title":"J Crohns Colitis."},{"key":"B23","doi-asserted-by":"publisher","first-page":"896476","DOI":"10.3389\/fimmu.2022.896476","article-title":"Curcumin and Curcuma longa extract in the treatment of 10 types of autoimmune diseases: a systematic review and meta-analysis of 31 randomized controlled trials","volume":"13","author":"Zeng","year":"2022","journal-title":"Front Immunol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"eadg7549","DOI":"10.1053\/j.gastro.2025.01.180","article-title":"Gut-associated lymphoid tissue attrition associates with response to anti-\u03b14\u03b27 therapy in ulcerative colitis","volume":"9","author":"Canales-Herrerias","year":"2024","journal-title":"Sci Immunol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1038\/s41467-024-45665-6","article-title":"Single-cell and spatial multi-omics highlight effects of anti-integrin therapy across cellular compartments in ulcerative colitis","volume":"15","author":"Mennillo","year":"2024","journal-title":"Nat Commun."},{"key":"B26","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1053\/j.gastro.2017.11.024","article-title":"Efficacy of indigo naturalis in a multicenter randomized controlled trial of patients with ulcerative colitis","volume":"154","author":"Naganuma","year":"2018","journal-title":"Gastroenterology."},{"key":"B27","doi-asserted-by":"publisher","first-page":"1781","DOI":"10.1142\/S0192415X22500756","article-title":"Chinese medicine in the treatment of ulcerative colitis: the mechanisms of signaling pathway regulations","volume":"50","author":"Zheng","year":"2022","journal-title":"Am J Chin Med."},{"key":"B28","doi-asserted-by":"publisher","first-page":"1504","DOI":"10.3390\/nu16101504","article-title":"Effects of mediterranean diet, curcumin, and resveratrol on mild-to-moderate active ulcerative colitis: a multicenter randomized clinical trial","volume":"16","author":"Erol Dogan","year":"2024","journal-title":"Nutrients."},{"key":"B29","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1159\/000511644","article-title":"Vedolizumab-induced liver injury","volume":"28","author":"Mascarenhas Saraiva","year":"2021","journal-title":"GE Port J Gastroenterol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"122829","DOI":"10.1016\/j.carbpol.2024.122829","article-title":"Astragalus polysaccharides alleviate DSS-induced ulcerative colitis in mice by restoring SCFA production and regulating Th17\/Treg cell homeostasis in a microbiota-dependent manner","volume":"349","author":"Zhang","year":"2025","journal-title":"Carbohydr Polym."},{"key":"B31","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1186\/s12951-023-01976-2","article-title":"\u201cDual sensitive supramolecular curcumin nanoparticles\u201d in \u201cadvanced yeast particles\u201d mediate macrophage reprogramming, ROS scavenging and inflammation resolution for ulcerative colitis treatment","volume":"21","author":"Han","year":"2023","journal-title":"J Nanobiotechnology."},{"key":"B32","doi-asserted-by":"publisher","first-page":"100512","DOI":"10.1016\/j.medj.2024.09.001","article-title":"Responsiveness of different disease activity indices in moderate-to-severe ulcerative colitis","volume":"6","author":"Solitano","year":"2025","journal-title":"Med."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1789083\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T04:16:32Z","timestamp":1775103392000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1789083\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,2]]},"references-count":32,"alternative-id":["10.3389\/fmed.2026.1789083"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2026.1789083","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,2]]},"article-number":"1789083"}}